Recombinant EGFR (Zalutumumab Biosimilar) anticorps

N° du produit ABIN7487875

Cet anticorps anti-EGFR (Zalutumumab Biosimilar) est un anticorps Mammalian Cells Monoclonal détectant EGFR (Zalutumumab Biosimilar) dans ELISA. Adapté pour Humain.

Aperçu rapide pour Recombinant EGFR (Zalutumumab Biosimilar) anticorps (ABIN7487875)

Antigène: EGFR (Zalutumumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Mammalian Cells

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR (Zalutumumab Biosimilar) est non-conjugé

Application: ELISA

Classe de qualité: Research Grade

Détail du produit anti-EGFR (Zalutumumab Biosimilar) anticorps

Expression System: Mammalian cells

Fonction: Zalutumumab Biosimilar - Anti-EGFR mAb

Attributs du produit: Antibody Type: IgG1-kappa

Purification: Recombinant antibody expressed in mammalien cells and purified.

Isotype: IgG1 kappa

Information d'application

Restrictions: For Research Use only

Stockage

Buffer: PBS pH 7.5

Stock: -80 °C

Stockage commentaire: store at -80°C

Détails sur EGFR (Zalutumumab Biosimilar)

Antigène: EGFR (Zalutumumab Biosimilar)

Classe de substances: Biosimilar

Sujet: HuMax-EGFr
Zalutumumab (proposed trade name HuMax-EGFR) is a high affinity, completely human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFR, also known as ErbB1/HER1). It is developed by Genmab and designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. Zalutumumab is derived from transgenic mice immunized with A431-derived EGFR.

Numéro CAS: 667901-13-5